Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"PeptiDream","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alnylam and PeptiDream Enter into Collaboration Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Peptide","graph2":"PeptiDream"}]

PeptiDream

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Alnylam and PeptiDream Enter into Collaboration Agreement

Details:

PeptiDream will select, optimize, and synthesize peptides for each receptor. Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.

Lead Product(s): Peptide-siRNA Conjugates

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Peptide

Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals

Deal Size: $2,200.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration July 29, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY